Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of QHRD107 Capsule Combined With Venclexta and Azacitidine in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia: a Single-arm, Open, Multicenter Phase IIa Study

NCT06532058 is registered in ClinicalTrials.gov with Changzhou Qianhong Bio-pharma Co., Ltd. as lead sponsor.

NCT NCT06532058
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06532058 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of QHRD107 Capsule Combined With Venclexta and Azacitidine in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia: a Single-arm, Open, Multicenter Phase IIa Study
Lead sponsor
Changzhou Qianhong Bio-pharma Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
August 10, 2023
Completion date
May 10, 2025
Enrollment
53 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory acute myeloid leukemia (r/r-aml)